Key Takeaways
- UNH started trading at $277.32, significantly below its 52-week peak of $606.36
- Wall Street firms reduced price targets — JPMorgan to $389, Truist to $370, UBS to $410
- Weiss Ratings issued a Sell rating downgrade in early March
- Fourth-quarter EPS of $2.11 slightly exceeded forecasts; revenue jumped 12.3% to $113.73 billion
- Analyst consensus holds at Moderate Buy with an average price target of $372.13
UnitedHealth Group (UNH) has experienced significant turbulence recently. Shares opened Monday at $277.32, trading substantially beneath both the 50-day moving average of $297.19 and the 200-day moving average of $324.39.
This represents a dramatic decline from the stock’s 52-week high of $606.36. The 52-week low currently sits at $234.60.
The healthcare giant’s market capitalization now stands at $251.71 billion, featuring a price-to-earnings ratio of 21.02 and a beta of 0.41.
UNH carries a debt-to-equity ratio of 0.72, while both its current ratio and quick ratio register at 0.79.
Last January, the company delivered fourth-quarter earnings of $2.11 per share, marginally surpassing the $2.09 consensus forecast. Revenue reached $113.73 billion, representing a 12.3% year-over-year increase and slightly exceeding analyst projections.
However, the Q4 EPS figure marks a substantial decline from the $6.81 reported during the comparable quarter one year prior.
Wall Street Reduces Price Expectations
Numerous prominent investment firms have scaled back their price projections in recent weeks.
JPMorgan reduced its target from $425 down to $389, Morgan Stanley adjusted downward from $411 to $409, and UBS lowered its projection from $430 to $410. Truist executed the most aggressive reduction, dropping from $410 to $370. Despite these cuts, all four firms maintained Buy or Overweight recommendations.
Weiss Ratings took a more pessimistic stance, downgrading UNH from Hold to Sell during early March.
MarketBeat’s current consensus rating stands at Moderate Buy, reflecting 17 Buy ratings, 8 Hold ratings, and 2 Sell ratings. The average 12-month price target of $372.13 suggests approximately 34% upside potential from present levels.
Regarding institutional ownership, significant movement has occurred. Wealth Enhancement Advisory Services reduced its position by 40.6% during Q4, disposing of 170,643 shares. Conversely, Norges Bank, Berkshire Hathaway, and Capital Research Global Investors either increased or established new positions throughout 2024. Institutional investors collectively control 87.86% of outstanding shares.
Regulatory Challenges Persist
Department of Justice scrutiny surrounding Medicare Advantage reimbursement practices continues to impact investor sentiment. While the company has secured at least one favorable legal ruling in that case, broader regulatory pressure regarding prior-authorization protocols and coverage denial practices remains unresolved.
Executives have previously outlined strategies to reduce certain Medicare Advantage membership and adjust product pricing in response to the changing cost landscape.
The company has issued FY2026 EPS guidance of approximately $17.75. Wall Street analysts currently project full-year EPS of $29.54 for the ongoing fiscal year.
UNH distributed a quarterly dividend of $2.21 per share on March 17, yielding approximately 3.2% annually. The current payout ratio stands at 67.02%.
On a more optimistic note, UnitedHealth recently unveiled plans for a nationwide expansion of its doula benefit program, an initiative that could enhance member retention and improve health outcomes within its value-based care framework.
